Literature DB >> 33527742

Peripheral synucleinopathy in Parkinson disease with LRRK2 G2385R variants.

Jing Yang1, Hao Wang1, Yanpeng Yuan1,2, Shiheng Fan2, Lanjun Li1, Chenyang Jiang1, Chengyuan Mao1, Changhe Shi1, Yuming Xu1,2.   

Abstract

OBJECTIVE: Recent studies demonstrated cutaneous phosphorylated α synuclein (p-syn) deposition in idiopathic and some monogenetic Parkinson disease (PD) patients, suggesting synucleinopathy identical to that in the brain. Although the LRRK2 Gly2385Arg (G2385R) variant is a common PD risk factor in the Chinese population, the pathogenesis of PD with G2385R variant has not been reported. We investigated whether synucleinopathy and small fiber neuropathy (SFN) are associated with the G2385R variant.
METHODS: We performed genotyping in 59 PD patients and 30 healthy controls from the skin biopsy database. The scale of SFN was assessed, as well as bright-field immunohistochemistry against antiprotein gene product 9.5 (PGP9.5) and double-labeling immunofluorescence with anti-PGP9.5 and anti-p-syn.
RESULTS: (1) p-syn deposited in the skin nerve fibers of G2385R carrier PD patients, which was a different pattern from noncarriers, without no difference observed between proximal and distal regions; (2) decreased distal intraepidermal nerve fiber density was found in both the G2385R carrier and the noncarrier PD group, and was negatively correlated with composite autonomic symptom score-31 item (COMPASS-31) scores; (3) PD patients with the G2385R variant showed a more peculiar clinical profile than noncarriers with a higher nonmotor symptoms scale, COMPASS-31 score, and levodopa equivalent dose, in addition to an increased prevalence of certain autonomic symptoms or rapid eye movement sleep behavior disorders.
INTERPRETATION: Synucleinopathy is related to the LRRK2 G2385R genotype and implies a different pathogenesis in G2385R variant carriers and noncarriers. This study also extended the clinical profiles of PD patients with the G2385R variant.
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Entities:  

Year:  2021        PMID: 33527742     DOI: 10.1002/acn3.51301

Source DB:  PubMed          Journal:  Ann Clin Transl Neurol        ISSN: 2328-9503            Impact factor:   4.511


  6 in total

Review 1.  Movement disorders and neuropathies: overlaps and mimics in clinical practice.

Authors:  Francesco Gentile; Alessandro Bertini; Alberto Priori; Tommaso Bocci
Journal:  J Neurol       Date:  2022-06-03       Impact factor: 6.682

Review 2.  Skin alpha-synuclein deposit patterns: A predictor of Parkinson's disease subtypes.

Authors:  Yihang Han; Di Wu; Yanjuan Wang; Jian Xie; Zhijun Zhang
Journal:  EBioMedicine       Date:  2022-05-26       Impact factor: 11.205

Review 3.  Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Jingxuan Huang; Yangfan Cheng; Chunyu Li; Huifang Shang
Journal:  Transl Neurodegener       Date:  2022-04-08       Impact factor: 8.014

4.  Self-Reported Visual Complaints in People with Parkinson's Disease: A Systematic Review.

Authors:  Iris van der Lijn; Gera A de Haan; Famke Huizinga; Fleur E van der Feen; A Wijnand F Rutgers; Catherina Stellingwerf; Teus van Laar; Joost Heutink
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

5.  Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson's disease.

Authors:  Toshiki Tezuka; Daisuke Taniguchi; Mariko Sano; Tomoyo Shimada; Yutaka Oji; Taiji Tsunemi; Aya Ikeda; Yuanzhe Li; Hiroyo Yoshino; Jun Ogata; Kahori Shiba-Fukushima; Manabu Funayama; Kenya Nishioka; Yuzuru Imai; Nobutaka Hattori
Journal:  NPJ Parkinsons Dis       Date:  2022-08-05

6.  α-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.

Authors:  Risa Isonaka; David S Goldstein; William Zhu; Esther Yoon; Debra Ehrlich; Alice B Schindler; Angela D Kokkinis; Marya S Sabir; Sonja W Scholz; Sara Bandres-Ciga; Cornelis Blauwendraat; Pedro Gonzalez-Alegre; Grisel Lopez; Ellen Sidransky; Derek P Narendra
Journal:  Mov Disord       Date:  2021-06-02       Impact factor: 9.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.